Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ISEE IVERIC bio (ISEE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About IVERIC bio Stock (NASDAQ:ISEE) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get IVERIC bio alerts:Sign Up Key Stats Today's Range$39.95▼$39.9550-Day Range$36.90▼$39.9552-Week Range$9.39▼$39.99VolumeN/AAverage Volume3.62 million shsMarket Capitalization$5.50 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewIVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.Read More… Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Receive ISEE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ISEE Stock News HeadlinesOpna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain InhibitorAugust 26, 2024 | venturebeat.comAstellas Pharma Inc (ALPMY)March 10, 2024 | investing.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 29, 2024 | Porter & Company (Ad)Apellis falls on potential EU snub for eye therapy (update)December 15, 2023 | msn.comAkoya Biosciences: 2024 Could Be The Year To Own Their StockDecember 7, 2023 | seekingalpha.comApellis adds safety warning to eye therapyDecember 1, 2023 | msn.comAstellas Completes Acquisition of Iveric BioJuly 11, 2023 | finance.yahoo.comB.Riley Financial Sticks to Its Hold Rating for IVERIC bio (ISEE)June 30, 2023 | markets.businessinsider.comSee More Headlines ISEE Stock Analysis - Frequently Asked Questions How were IVERIC bio's earnings last quarter? IVERIC bio, Inc. (NASDAQ:ISEE) issued its earnings results on Wednesday, March, 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.10. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that IVERIC bio investors own include Alibaba Group (BABA), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings3/01/2023Today10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ISEE CUSIPN/A CIK1410939 Webivericbio.com Phone(609) 474-6755FaxN/AEmployees163Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-185,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.00% Return on Assets-46.15% Debt Debt-to-Equity Ratio0.20 Current Ratio15.53 Quick Ratio15.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.43 per share Price / Book9.02Miscellaneous Outstanding Shares137,780,000Free Float134,063,000Market Cap$5.50 billion OptionableOptionable Beta1.06 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:ISEE) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IVERIC bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IVERIC bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.